PANAVIR solution for injection 0.04 mg/ml 5 ml 2 pcs - antiviral and immunomodulatory preparation

PANAVIR® Russian broad-spectrum antiviral preparation. Panavir is a biologically active substance - a plant polysaccharide belonging to the class of hexose glycosides.

Ingredients:

active substance: Panavir® (potato shoots sum of polysaccharides) - 200 mcg;

excipients: sodium chloride - 0.045 g, water for injection - up to 5 ml.

Direction:

Antiviral and immunomodulatory agent.

Action:

Panavir® - purified extract of shoots of the Solanum tuberosum plant; the main active ingredient is a hexose glycoside consisting of glucose, rhamnose, arabinose, mannose, xylose, galactose, and uronic acids.

The preparation Panavir® is an antiviral and immunomodulatory agent. Increases the body's nonspecific resistance to various infections and promotes the induction of alpha and gamma interferons by blood leukocytes.

In therapeutic doses, the preparation is well tolerated.

Tests have shown the absence of mutagenic, teratogenic, carcinogenic, allergenic and embryotoxic effects. In preclinical studies on laboratory animals, no negative effects on reproductive function and fetal development were established.

It has anti-inflammatory properties in experimental models of exudative edema, chronic proliferative inflammation and in the pseudoallergic inflammatory reaction test to concanavalin A.

An analgesic effect has been shown in models of neurogenic pain and pain caused by inflammation and thermal irritation.

Has an antipyretic effect.

In a model of parkinsonian syndrome caused by systemic administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, neuroprotective properties were shown.

Has the ability to improve the functions of the retina and optic nerve.

It has wound-healing properties in a gastric ulcer model.

When administered intravenously, polysaccharides are detected in the blood within 5 minutes after administration and are captured by the cells of the reticuloendothelial system of the liver and spleen. Elimination begins quickly; after 20-30 minutes, polysaccharides are found in the urine and exhaled air.

Indications:

• Herpesvirus infections of various localizations (including recurrent genital herpes, herpes zoster and ophthalmic herpes).
• Secondary immunodeficiency states due to infectious diseases.
• Cytomegalovirus infection, including in patients with recurrent miscarriage.
• Used in women with chronic viral infection and interferon deficiency in preparation for pregnancy.
• Chronic cytomegalovirus infection in the acute stage in pregnant women in the 2nd and 3rd trimester as part of complex therapy.
• Human papillomavirus infection (anogenital warts) as part of complex therapy.
• Peptic ulcer of the stomach and duodenum in patients with long-term scarring ulcers and symptomatic ulcers of the gastroduodenal zone as part of complex therapy.
• Tick-borne encephalitis to reduce the viral load and relieve neurological symptoms (anisoreflexia, decreased reflexes, pain at the exit points of cranial nerves, nystagmus) as part of complex therapy.
• Rheumatoid arthritis combined with herpesvirus infection in immunocompromised patients (to enhance the analgesic and anti-inflammatory effect of the main therapy), as part of complex therapy.
• ARVI and influenza as part of complex therapy.
• Panavir® is used in complex therapy of chronic bacterial prostatitis.

Use during pregnancy and breastfeeding:

Use is possible in the II and III trimester according to the indication of chronic cytomegalovirus infection in the acute stage as part of complex therapy. In other cases, use is possible only if the expected benefit to the mother outweighs the potential risk to the fetus. If it is necessary to use the preparation during lactation, breastfeeding should be stopped while taking the preparation .

Contraindications:

• Individual intolerance. Panavir® should not be used by patients who are allergic to the constituent components of the preparation : glucose, mannose, rhamnose, arabinose, xylose.
• Lactation period.
• Children under 12 years of age.

Side effects:

The preparation is well tolerated; possible complications may be associated with individual intolerance and hypersensitivity to the components of the preparation .

However, if any unwanted side effects occur, you should stop administering the preparation and consult your doctor.

If you notice any other side effects not listed in the instructions, tell your doctor.

How to take, course of administration and dosage:

• Panavir® should be administered intravenously as a slow stream.
• The therapeutic dose of the preparation is 200 mcg of active substance (contents of one ampoule or bottle).
• For the treatment of herpes virus infections and tick-borne encephalitis, apply twice with an interval of 48 or 24 hours. If necessary, the course of treatment can be repeated after 1 month.
• For the treatment of cytomegalovirus and human papillomavirus infections, it is used three times during the first week with an interval of 48 hours and twice during the second week with an interval of 72 hours.
• For the treatment of chronic cytomegalovirus infection in the acute stage in pregnant women in the second and third trimester, it is used three times during the first week with an interval of 48 hours and twice during the second week with an interval of 72 hours.
• For the treatment of gastric and duodenal ulcers in the acute phase and symptomatic ulcers of the gastroduodenal zone, 5 intravenous injections are used every other day for 10 days.
• For the treatment of rheumatoid arthritis combined with herpesvirus infection in immunocompromised patients, 5 intravenous injections are used with an interval of 24-48 hours, if necessary, repeat the course after 2 months.
• For the treatment of ARVI and influenza, 2 intravenous injections are used with an interval of 18-24 hours.
• For the treatment of patients with chronic bacterial prostatitis, 5 intravenous injections are used with an interval of 48 hours.

Application in pediatrics:

Panavir® is prescribed to children over 12 years of age at a dose of 100 mcg intravenously once a day.

For the treatment of herpes virus infections and tick-borne encephalitis, it is used twice with an interval of 48 or 24 hours. If necessary, the course of treatment can be repeated after 1 month.

For the treatment of cytomegalovirus and human papillomavirus infections, it is used three times during the first week with an interval of 48 hours and twice during the second week with an interval of 72 hours.

Overdose: no cases of overdose have been reported. The results of preclinical studies indicate low toxicity of the preparation .

Special instructions: when used in preparation for pregnancy, it helps reduce the frequency of reproductive losses due to cytomegalovirus and herpesvirus infections.If the solution becomes cloudy, the preparation is considered unsuitable for use.

Influence on the ability to drive vehicles and mechanisms:

There is no data on the possibility of a negative effect of the preparation on the ability to drive vehicles and carry out potentially hazardous activities that require special attention and speed of psychomotor reactions.

Release form:

Solution for intravenous administration 0.04 mg/ml.Transparent or slightly opalescent, colorless or light brown liquid, odorless.

5 ml of solution in ampoules or neutral glass bottles with a capacity of 5 ml, sealed with rubber stoppers with rolled aluminum caps.

2 ampoules in a blister pack, 1 blister pack of 2 ampoules, along with instructions for use and an ampoule knife or scarifier in a cardboard pack.

When packaging in ampoules with a colored dot and a cut or a colored break ring on the ampoule, a scarifier or ampoule knife is not inserted.

Storage conditions:in a place protected from light, at a temperature of 2 to 25 ° C. Keep out of the reach of children.

Best before date: 5 years. Do not use after the expiration date stated on the packaging.

Guaranteed authenticity and quality:

100% original product from LLC NATIONAL RESEARCH COMPANY (Russian Federation)

Development:

LLC National Research Company, which combines the full cycle from development to implementation of both medicines and medical equipment and other high-tech products of chemical physics, microbiology and medicine:

• develops original medicines, biologically active additives, cosmetics;
• conducts a full cycle of preclinical and clinical studies;
• develops and implements original medical equipment;
• cooperates with distributors in Russia and CIS countries;
• ready to cooperate with authors of innovative drugs in the development and registration of new drugs.

The most famous brands of the company: Panavir, Biopokrov, Forvet.

At the stage of development and registration there are original antiviral, antibacterial, antifungal drugs, immunomodulators, anti-stroke drugs, neuroprotectors, anthelmintic drugs, and drugs in ultra-low doses.

Production:

ELLARA (Russian Federation)